Role of neuroinflammation in the pathogenesis of glaucomatous optic neuropathy
DOI: 10.32364/2311-7729-2022-22-2-116-121
E.A. Egorov1, V.E. Korelina2, D.V. Cherednichenko3, I.R. Gazizova3
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2LLC "American Medical Clinic", St. Petersburg, Russian Federation
3N.P. Bekhtereva Institute of the Human Brain, St. Petersburg, Russian Federation
This article reviews recent studies on the etiology and pathogenesis of primary open-angle glaucoma (POAG). POAG is now considered a neurodegenerative disease associated with neuroinflammation. Neuroglia plays a key role in the development of neuroinflammation. In impaired homeostasis, microglia is activated to prevent retinal alterations triggered by glutamate excitotoxicity. Macrophages, being still active, release cytokines in the extracellular space and produce matrix metalloproteinases. The result is an increased degradation of collagen fibers of the lamina cribrosa and development of glaucomatous optic neuropathy. Macroglia (astrocytes and Muller cells) are also involved in retinal immunoregulation. Astrocytes produce neurotrophic brain factor which promote the survival of damaged neurons. Additionally, these cells secrete fibrillar proteins that regenerate the extracellular matrix but form a glial scar, thereby inhibiting axonal transport and limiting t he regeneration of damaged axons. The activation of microglia and macroglia in glaucoma precedes the loss of retinal ganglion cells. Determining the activity of retinal ganglion cells helps identify specific biomarkers of early glaucoma. Early diagnosis of POAG prevents irreversible damage. The authors discuss potential ways to regulate the activity of glia by stimulating the release of neurotrophic factors and suppressing glia hyperactivity.
Keywords: primary open-angle glaucoma, neurodegenerative disease, neuroinflammation, macroglia, microglia, neurotrophic factors.
For citation: Egorov E.A., Korelina V.E., Cherednichenko D.V., Gazizova I.R. Role of neuroinflammation in the pathogenesis of glaucomatous optic neuropathy. Russian Journal of Clinical Ophthalmology. 2022;22(2):116–121 (in Russ.). DOI: 10.32364/2311-7729-2022-22-2-116-121.
About the authors:
Evgeniy A. Egorov — Dr. Sc. (Med.), Professor, Head of the Academician A.P. Nesterov Department of Ophthalmology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-6495-7173.
Viktoria E. Korelina — C. Sc. (Med.), ophthalmologist, LLC "American Medical Clinic"; 78, letter A, river Moika embankment, St. Petersburg, 190000, Russian Federation; ORCID iD 0000-0003-2022-5912.
Denis V. Cherednichenko — C. Sc. (Med.), First Deputy Director, N.P. Bekhtereva Institute of the Human Brain; 12а, Academician Pavlov str., St. Petersburg, 197376, Russian Federation; ORCID iD 0000-0002-8957-8970.
Ilmira R. Gazizova — Dr. Sc. (Med.), Scientific Secretary, Head of the Department of Ophthalmology, N.P. Bekhtereva Institute of the Human Brain; 12а, Academician Pavlov str., St. Petersburg, 197376, Russian Federation; ORCID iD 0000-0003-4611-9931.
Contact information: Ilmira R. Gazizova, e-mail: ilmiraufa88@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 10.02.2022.
Revised 10.03.2022.
Accepted 04.04.2022.
2. McKinnon S.J. Glaucoma: ocular Alzheimer’s disease? Front Biosci. 2003;8:1140–1156. DOI: 10.2741/1172. PMID: 12957857.
3. Yücel Y.H., Zhang Q., Gupta N. et al. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol. 2000;118(3):378–384. DOI: 10.1001/archopht.118.3.378.
4. Gupta N., Ang L.C., Noel de Tilly L., Yücel Y.H. Human glaucoma and neuronal degeneration in the intracranial optic nerve, lateral geniculate nucleus and visual cortex of the brain. Br J Ophthal. 2006;90:674–678. DOI: 10.1136/bjo.2005.086769.
5. Alekseev V.N., Gazizova I.R., Nikitin D.N. Morphological features of the central parts of the visual analyzer in experimental glaucoma. In: Modern technologies of diagnosis and treatment of lesions of the organ of vision: Collection of scientific papers based on the materials of the conference. SPb.; 2013:13–14 (in Russ.).
6. Anichkov N.M., Korzhevsky D.E., Zakhryapin M.S. et al. The brain and open-angle glaucoma. Practical medicine. 2012;4(59):157–161 (in Russ.).
7. Gazizova I.R. Glaucoma as a neurodegenerative disease. Clinical Ophthalmology. 2014;3:123–127 (in Russ.).
8. Yücel Y.H., Zhang Q., Weinreb R.N. et al. Atrophy of relay neurons in mango- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci. 2001;42(13):3216–3222.
9. Gazizova I.R. New aspects of the pathogenesis of glaucoma optic neuropathy: thesis. SPb.; 2013 (in Russ.).
10. Yücel Y.H., Zhang Q., Weinreb R.N. et al. Effects of retinal ganglion cell loss on mango-, parvo-, koniocellular pathway in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res. 2003;22(4):465–481. DOI: 10.1016/s1350-9462(03)00026-0.
11. Gupta N., Zhang Q., Kaufman P.L. et al. Chronic ocular hypertension induces dendrite pathology in the lateral geniculate nucleus of the brain. Exper Eye Research. 2007;84:176–184. DOI: 10.1016/j.exer.2006.09.013.
12. De Lau L.M., Breteler M.M. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535. DOI: 10.1016/S1474-4422(06)70471-9.
13. Sharma S., Lipincott W. Biomarkers in Alzheimer’s Disease-Recent Update. Current Alzheimer research. 2017;14:156–164. DOI: 10.2174/1567205014666170220141822.
14. Orr C.F., Rowe D.B., Halliday G.M. An inflammatory review of Parkinson’s disease. Prog Neurobiol. 2002;68(5):325–340. DOI: 10.1016/s0301-0082(02)00127-2.
15. Erichev V.P., Tumanov V.P., Panyushkina L.A., Fedorov A.A. Comparative analysis of morphological changes in the optic centers in patients with glaucoma and Alzheimer’s disease. National Journal glaucoma. 2014;13(3):5–13 (in Russ.).
16. de Hoz R., Rojas B., Ramírez A.I. et al. Retinal Macroglial Responses in Health and Disease. Biomed Res Int. 2016;11(55):2954721. DOI: 10.1155/2016/2954721.
17. Gupta N., Ang L.C., Girard E., Yücel Y.H. Retinal tau pathology in human glaucomas. Can J Ohthal. 2008;43:53–60. DOI: 10.3129/i07-185.
18. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and conseguences. Prog Retin Eye Res. 2006;25:490–513. DOI: 10.1016/j.preteyeres.2006.07.003.
19. Bayer A.U., Ferrari F., Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol. 2002;47:165–168. DOI: 10.1159/000047976.
20. Trick G.L., Trick L.R., Morris P., Wolf M. Visual field loss in senile dementia of the Alzheimer’s disease type. Neurology. 1995;45:68–74. DOI: 10.1212/wnl.45.1.68.
21. Den Haan J., Verbraak F.D., Visser P.J., Bouwman F.H. Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimers Dement (Amst). 2017;6:162–170. DOI: 10.1016/j.dadm.2016.12.014.
22. Cerquera-Jaramillo M.A., Nava-Mesa M.O., González-Reyes R.E. et al. Visual Features in Alzheimer’s Disease: From Basic Mechanisms to Clinical Overview. Neural Plast. 2018;14:2941783. DOI: 10.1155/2018/2941783.
23. Jones-Odeh E., Hammond C.J. How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis? Eye (Lond). 2015;29(10):1270–1284. DOI: 10.1038/eye.2015.158.
24. Panyushkina L.A. Clinical and morphological features of the visual pathway in glaucoma and Alzheimer’s disease: thesis. M.; 2015 (in Russ.).
25. Gauthier A.C., Liu J. Neurodegeneration and Neuroprotection in Glaucoma. Yale J Biol Med. 2016;89(1):73–79.
26. Singhal G., Jaehne E.J., Corrigan F. et al. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014;8:315. DOI: 10.3389/fnins.2014.00315.
27. Voet S., Prinz M., van Loo G. Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology. Trends Mol Med. 2019;25(2):112–123. DOI: 10.1016/j.molmed.2018.11.005.
28. Yang Z., Quigley H.A., Pease M.E. et al. Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Invest Ophthalmol Vis Sci. 2007;48(12):5539–5548. DOI: 10.1167/iovs.07-0542.
29. Glass C.K., Saijo K., Winner B. et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918–934. DOI: 10.1016/j.cell.2010.02.016.
30. Ransohoff R.M., Cardona A.E. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468(7321):253–622. DOI: 10.1038/nature09615.
31. Dudvarski S.N., Teodorczyk M., Ploen R. et al. Microglia-blood vessel interactions: a double-edged sword in brain pathologies. Acta Neuropathol. 2016;131(3):347–363. DOI: 10.1007/s00401-015-1524-y.
32. Verkhratsky A., Butt A.M. Glial physiology and pathophysiology. Oxford: Wiley-Blackwell-John Wiley & Sons; 2013.
33. Neufeld A.H., Liu B. Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist. 2003;9(6):485–495. DOI: 10.1177/1073858403253460.
34. Sierra A., Abiega O., Shahraz A., Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci. 2013;7:6. DOI: 10.3389/fncel.2013.00006.
35. Basilico B., Pagani F., Grimaldi A. et al. Microglia shape presynaptic properties at developing glutamatergic synapses. Glia. 2019;67:53–67. DOI: 10.1002/glia.23508.
36. Harada T., Harada C., Kohsaka S. et al. Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci. 2002;22(21):9228–9236. DOI: 10.1523/JNEUROSCI.22-21-09228.2002.
37. Korelina V.E. Study of correction of lipid peroxidation by antioxidants in experimental glaucoma (experimental study): thesis. SPb.; 1999 (in Russ.).
38. Vilhardt F., Haslund-Vinding J., Jaquet V., McBean G. Microglia antioxidant systems and redox signalling. Br J Pharmacol. 2017;174(12):1719–1732. DOI: 10.1111/bph.13426.
39. Callahan M.K., Ransohoff R.M. Analysis of leukocyte extravasation across the blood-brain barrier: conceptual and technical aspects. Curr Allergy Asthma Rep. 2004;4(1):65–73. DOI: 10.1007/s11882-004-0046-9.
40. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91(2):461–553. DOI: 10.1152/physrev.00011.2010.
41. Chernykh V.V., Khodzhaev N.S., Trunov A.N. et al. Peculiarities of pathogenesis of primary open angle glaucoma with normalized intraocular pressure, new approaches to the integrated treatment. Bulletin SB RAMS. 2014;34(3):6–12 (in Russ.).
42. Trunov A.N., Bgatova N.P., Eremina A.V. et al. New approaches to the evaluation of inflammatory disorders intensity in pathogenesis of primary open angle glaucoma. Allergology and immunology. 2016;17(2):107–111 (in Russ.).
43. Markiewicz L., Pytel D., Mucha B. et al. Altered Expression Levels of MMP1, MMP9, MMP12, TIMP1, and IL-1P as a Risk Factor for the Elevated IOP and Optic Nerve Head Damage in the Primary Open-Angle Glaucoma Patients. Biomed Res Int. 2015;15:812503. DOI: 10.1155/2015/812503.
44. Provis J.M., Diaz C.M., Penfold P.L. Microglia in human retina: a heterogeneous population with distinct ontogenies. Perspect Dev Neurobiol. 1996;3(3):213–222.
45. Alekseev V.N., Gazizova I.R. New molecular and biological aspects of neurodegeneration in glaucoma. Clinical Ophthalmology. 2014;2:85–90 (in Russ.).
46. Lee D., Shim M.S., Kim K.Y. et al. Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2014;55(2):993–1005. DOI: 10.1167/iovs.13-12564.
47. Adornetto A., Russo R., Parisi V. Neuroinflammation as a target for glaucoma therapy. Neural Regen Res. 2019;14(3):391–394. DOI: 10.4103/1673-5374.245465.
48. Vecino E., Rodriguez F.D., Ruzafa N. et al. Glia-neuron interactions in the mammalian retina. Prog Retin Eye Res. 2016;51:1–40. DOI: 10.1016/j.preteyeres.2015.06.003.
49. Alekseev V.N., Korelina V.E., Martynova E.B. Therapeutic pathomorphosis of experimental glaucoma (experimental study). In: VII All-Russian School of Ophthalmologists: thesis. M.; 2008:17–23 (in Russ.).
50. Samusenko I.A., Alekseev V.N., Abuzayed V.N. Morphological appearance of the therapeutical patomorphosis of the glaucomatous optical neuropathy at the experimental glaucoma. National Journal glaucoma. 2003;4:3–9 (in Russ.).
51. Bringmann A., Yandiev I., Pannike T. et al. Zelluläre Signalübertragung und Faktoren, die an der Müller-Zell-Gliose beteiligt sind: neuroprotektive und schädliche Wirkungen. Progr Retin Augenres. 2009;28:423–451.
52. Hernandez M.R. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res. 2000;19(3):297–321. DOI: 10.1016/s1350-9462(99)00017-8.
53. Reichenbach A., Bringmann A. Glia of the human retina. Glia. 2020;68(4):768–796. DOI: 10.1002/glia.23727.
54. Vernazza S., Tirendi S., Bassi A.M. et al. Neuroinflammation in primary open-angle glaucoma. GCM. 2020;9(10):3172. DOI: 10.3390/jcm9103172.
55. Sommer A., Winner B., Prots I. The Trojan horse — neuroinflammatory impact of T cells in neurodegenerative diseases. Molecular Neurodegeneration. 2017;12(1):78. DOI: 10.1186/s13024-017-0222-8.
56. Voet S., Prinz M., van Loo G. Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology. Trends Mol Med. 2019;25(2):112–123. DOI: 10.1016/j.molmed.2018.11.005.
57. Gupta V., Gupta V.B., Chitranshi N. et al. One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina. Cell Mol Life Sci. 2016;73(22):4279–4297. DOI: 10.1007/s00018-016-2295-x.
58. Hart N.J., Koronyo Y., Black K.L., Koronyo-Hamaoui M. Ocular indicators of Alzheimer’s: Exploring disease in the retinа. Acta Neuropathol. 2016;132:767–787. DOI: 10.1007/s00401-016-1613-6.
59. Chiasseu M., Alarcon-Martinez L., Belforte N. et al. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer’s disease. Mol Neurodegener. 2017;12(1):58. DOI: 10.1186/s13024-017-0199-3.
60. Fernández-Albarral J.A., Salobrar-García E., Martínez-Páramo R. et al. Retinal glial changes in Alzheimer’s disease — A review. J Ophtalm. 2019;12(3):198–207. DOI: 10.1016/j.optom.2018.07.001.
61. Alekseev V.N., Korelina V.E., Shasha Ch. Neuroprotection by new antioxidant Rexode in experimental glaucoma. Clinical ophthalmology. 2008;3:82–83 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать